{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000085","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.931842+00:00","generated_at":"2026-05-31T10:21:08.552099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurogene Q2 net loss $18.5M; NGN-401 gets RMAT and START FDA designations","bullets":["Cash and equivalents $153.9M as of June 30, 2024; expected to fund operations into 2H 2026.","Net loss $18.5M in Q2 2024 vs $11.9M in Q2 2023; R&D expenses rose to $15.7M from $10.3M.","NGN-401 for Rett syndrome received RMAT designation and was selected for FDA START Pilot Program.","First patient dosed in high-dose Cohort 2; interim efficacy data from Cohort 1 expected Q4 2024.","Enrollment complete in NGN-101 for CLN5 Batten disease; data and regulatory update in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000085","json":"https://secwatch.observer/filing/0001404644-24-000085.json","markdown":"https://secwatch.observer/filing/0001404644-24-000085.md","text":"https://secwatch.observer/filing/0001404644-24-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/0001404644-24-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000085/ngne-20240809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:21:08.552099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}